Failure of adjunctive cytomegalovirus intravenous immune globulin to improve efficacy of ganciclovir in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: a phase 1 study.
AUTOR(ES)
Jacobson, M A
RESUMO
Six men with acquired immunodeficiency syndrome (AIDS) and cytomegalovirus (CMV) retinitis, treated with combined ganciclovir induction therapy and hyperimmune globulin (CMV-IGIV) for 10 days followed by CMV-IGIV alone, had a median time to retinitis progression shorter (7 days) than had eight historical controls given ganciclovir maintenance therapy (54 days; P = 0.06) and similar to that in eight controls given ganciclovir for 10 days only (19 days; P = 0.97). CMV-IGIV, which also failed to inhibit CMV replication in blood and urine, did not appear to add markedly to the efficacy of ganciclovir in acquired immunodeficiency syndrome-associated CMV retinitis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=171546Documentos Relacionados
- Cytomegalovirus retinitis: a manifestation of the acquired immune deficiency syndrome (AIDS).
- Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
- Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
- High dose intravitreal ganciclovir for CMV retinitis: a shelf life and cost comparison study.
- Home treatment of cytomegalovirus retinitis with intravenous Ganciclovir.
